A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.

Funda Meric-Bernstam,Emiliano Calvo,Victor Moreno,Hyun Cheol Chung,Yeon Hee Park,Yung-Jue Bang,Lee S. Rosen,Monica M. Mita,Ignacio Garrido–Laguna,Abraham C.F. Leung,Harman Dube,Wei Zhong,Xiaoying Chen,Rula Dawaher,Giuseppe Curigliano

A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.

2020

Funda Meric-Bernstam
Emiliano Calvo
Victor Moreno
Hyun Cheol Chung
Yeon Hee Park
Yung-Jue Bang
Lee S. Rosen
Monica M. Mita
Ignacio Garrido–Laguna
Abraham C.F. Leung
Harman Dube
Wei Zhong
Xiaoying Chen
Rula Dawaher
Giuseppe Curigliano

1039Background: PF-06804103 is an anti-HER2 immunoglobulin G1 antibody-drug conjugate (ADC), comprising an anti-HER2 monoclonal antibody conjugated with a cleavable linker to the cytotoxic agent Au...

Keywords:

Oncology
Anti-HER2 Antibody
Internal medicine
Pathology
Drug
in patient
dose escalation
Conjugate
Medicine
Tolerability
Monoclonal antibody
Pharmacology
Cytotoxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations